Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SORCE trial of adjuvant sorafenib versus placebo after nephrectomy for renal cell carcinoma
NL-OMON50236Phase 3Active, not recruiting
- Sponsor
- UroGen Pharma
- Start
- Aug 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sorafenib in renal cell carcinoma (RCC) (3 arms), sponsored by UroGen Pharma. Primary endpoint: Disease-free survival. Started Aug 2009; status: active, not recruiting.
02
Drugs
sorafenib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NL-OMON50236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50236.